Skip to content

Precigen PGEN AFS Securities

AFS Securities at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$308.45M-41.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$121M+76.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$162.99M+7,973%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's AFS securities?
Precigen (PGEN) reported AFS securities of $489K in Q1 2026.
How has Precigen's AFS securities changed year-over-year?
Precigen's AFS securities decreased by 34.8% year-over-year, from $750K to $489K.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.